Colchicine was the first drug approved to treat heart disease by targeting inflammation.
Colchicine has anti-fibrotic properties, e.g. in the lungs.
This hints that it may actually be working, in part, by inhibiting IL-11. This is a big deal because blocking IL-11 extends lifespan of mice by 25%.
The main company working on anti-IL-11 therapies in humans is beginning trials in pulmonary fibrosis.
It may not be a coincidence that colchicine has been previously investigated as a treatment for pulmonary fibrosis.


